Good: EBITDA and cash flow positive, group receipts better than whatever happened in 2Q23 and 4Q22 (by basic arithmetic). Whatever cutbacks they are doing aren't impacting the bottom line.
Bad: Group receipts in USD terms still worse than anything since 4Q15 aside from those 2 quarters. FLN still valued like a growth company that hasn't grown for 8 years.
Ugly: Talking about "3 companies" when discussing EBITDA, but only disclosing segment information by marketplace + Escrow. Mystery grab bag of metrics each report (GPV->GMV switch, no breakdown of where FLN earns money by USD/AUD).
A few solid quarters and they might be OK, but it's hard to picture what the end game is here. They're not going to get out of 4th place (behind UPWK, FVRR and Toptal, who are at about 18/10/5x FLN's revenues respectively) by organic growth - especially when the competition is growing faster than they are and is generously funded in US markets.
- Forums
- ASX - By Stock
- FLN
- Ann: 3Q23 Business Update
Ann: 3Q23 Business Update, page-4
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FLN (ASX) to my watchlist
|
|||||
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $85.67M |
Open | High | Low | Value | Volume |
21.0¢ | 21.5¢ | 18.5¢ | $38.66K | 191.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11230 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 21860 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11230 | 0.190 |
1 | 99854 | 0.185 |
1 | 23571 | 0.180 |
1 | 16000 | 0.175 |
2 | 41662 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 21860 | 1 |
0.220 | 12752 | 2 |
0.225 | 13000 | 1 |
0.230 | 490 | 1 |
0.240 | 4166 | 1 |
Last trade - 14.55pm 24/07/2024 (20 minute delay) ? |
Featured News
FLN (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online